Key result
Elevated EROA/TAPSE ratio linked to ~144% more major events after tricuspid annuloplasty.
Why the study?
Secondary tricuspid regurgitation severity assessment does not account for right heart function, leaving its prognostic implications relative to right ventricular dysfunction unknown in patients undergoing tricuspid annuloplasty.
Does a pre-procedural EROA/TAPSE ratio >3.42 predict adverse events in patients undergoing tricuspid annuloplasty?
Observational (n=290)
No
Does a pre-procedural EROA/TAPSE ratio >3.42 predict adverse events in patients undergoing tricuspid annuloplasty?
Absolute Event Rate: 44% vs 18%
p-value: p=<0.001
A pre-procedural EROA/TAPSE ratio >3.42 is independently associated with an increased risk of heart failure hospitalization and death in patients undergoing tricuspid annuloplasty, highlighting its potential for risk stratification.
Should not yet change practice in tricuspid annuloplasty; hypothesis-generating for EROA/TAPSE-guided risk stratification.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tse et al. (2023) conducted an observational in Secondary tricuspid regurgitation (n=290). EROA/TAPSE ratio >3.42 vs. EROA/TAPSE ratio ≤3.42 was evaluated on Composite of all-cause mortality and heart failure hospitalization (p=<0.001). An effective regurgitant orifice area to tricuspid annular plane systolic excursion ratio >3.42 was associated with a significantly higher rate of adverse events (44% vs 18%) compared to a ratio ≤3.42 in patients undergoing tricuspid annuloplasty.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: